Investigating the Role of Urokinase in Cancer Metastasis: A Review

The greatest cause of cancer-related mortality is cancer metastasis, which is the spread of cancer cells from the original tumour to distant areas. Urokinase (uPA) is one of the important proteases involved in this process. By encouraging cell migration, invasion, and angiogenesis, uPA plays a critical part in the spread of cancer. Numerous cancers have an overexpressed uPA system, which is linked to a poor prognosis and a higher chance of metastasis. The project focuses on the state of the science around uPA inhibitors as a possible therapeutic for preventing or treating cancer metastasis. Different kinds of uPA inhibitors, including as monoclonal antibodies, small molecule inhibitors, and plasminogen activator inhibitors (PAIs), have been created and have showed promise in preclinical investigations. To prove their effectiveness in treating cancer patients, more study is necessary. A promising strategy for preventing or treating cancer metastasis involves targeting the uPA system with specific inhibitors or through techniques like gene therapy, anti-uPA/uPAR antibodies, uPA-targeted nanoparticles, and dual inhibitors that target multiple proteases involved in cancer metastasis. uPA inhibitors have also been researched as potential indicators for estimating the likelihood of cancer spread.